论文部分内容阅读
羟苄四唑头孢菌素(Cefamandole、CMD)为1972年美国E.Lilly公司创制的一种第二代头孢菌素,国外1978年应用于临床。上海第三制药厂抗生素研究所于1979年研制成功,以羟苄四唑头孢菌素甲酯钠(Cefamandole nafafe、商品名头孢孟多钠)作为临床制剂。 本品是一种杀菌作用较强的新型头孢菌素,兼有第一代和第三代头孢菌素的某些优点,对大多数革蓝氏阳性菌,部分阴性菌和梭状芽孢杆菌具有强大抗菌活性,特别对流感杆菌、大肠杆菌、奇异变形杆菌、雷极氏变形杆菌、伤寒杆菌、痢疾杆菌及肺炎杆菌等的作用比第一代头孢菌素强,但对肠球菌,绿脓杆菌及脆弱拟杆菌则无效。
Cefmenoxime (Cefamandole, CMD) was a second-generation cephalosporin invented by E.Lilly in 1972 and applied abroad in 1978. Shanghai Third Pharmaceutical Factory Antibiotics Institute was successfully developed in 1979, with cefotaxime sodium (cefamandole nafafe, cefmetazepor sodium) as a clinical preparation. This product is a new bactericidal effect of new cephalosporins, both the first and third generation cephalosporins some of the advantages of most of the Gram-positive bacteria, some of the negative bacteria and Clostridium has Strong antibacterial activity, especially against influenza bacilli, Escherichia coli, Proteus mirabilis, Proteus mirabilis, typhoid bacillus, dysentery bacilli and Klebsiella pneumoniae than the first-generation cephalosporins stronger, but Enterococcus, Pseudomonas aeruginosa And Bacteroides fragilis is invalid.